Skip to main content
Premium Trial:

Request an Annual Quote

Congenica Raises $3.3M in Series A Financing

NEW YORK (GenomeWeb) – Cambridge, UK-based Congenica today announced it has raised £2.2 million ($3.3 million) in Series A financing from Amadeus Capital Partners and Cambridge Innovation Capital.

The firm has developed Sapientia, a platform to screen whole-genome sequencing data to identify novel genetic mutations and highlight those associated with genetic disorders.

Congenica, a spinout of The Wellcome Trust Sanger Institute, will use the funds to further develop its technology, the firm said in a statement.

"We have an excellent investor base and have now achieved £5 million in funding and grants and which will help us take the technology into the clinic and accelerate our growth," Congenica CEO Tom Weaver said in a statement.

In March, Congenica received a share of £8 million in research grants awarded by Genomics England to improve genomic data analysis.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.